Patents Represented by Law Firm Cooley Godward Castro Huddleson & Tatum
  • Patent number: 5688784
    Abstract: There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid and maltol.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 18, 1997
    Assignee: The University of British Columbia
    Inventors: John Hugh McNeill, Hamid Reza Hoveyda, Chris Orvig, Ying Zhou, Jere Douglas Fellmann
  • Patent number: 5635369
    Abstract: Yeast strains and a method of expression in yeast of the monooxygenase activity of heterologous cytochromes P450 are disclosed. Within the genome of the yeast strain, genes for NADPH-cytochrome P450 reductase and cytochrome b5 are stably integrated and coexpressed. The genome is transformed with a plasmid carrying a cassette for the expression of a heterologous P450 gene.
    Type: Grant
    Filed: January 13, 1994
    Date of Patent: June 3, 1997
    Assignee: Centre National De La Recherche Scientifique
    Inventors: Denis Pompon, Christophe Cullin, Gilles Truan, Philippe Urban, Piotr Slonimski
  • Patent number: 5629414
    Abstract: Genetic material encoding p30 and B1 peptides of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: May 13, 1997
    Assignee: The Board of Trustees of the Leeland Stanford Junior University
    Inventors: John C. Boothroyd, James L. Burg, Lloyd H. Kasper
  • Patent number: 5605825
    Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly racl and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 25, 1997
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Arie Abo, George A. Martin
  • Patent number: 5603685
    Abstract: A pessary device, comprising a first inflatable chamber adapted to fit in the vestibule of the vaginal cavity of a human when inflated, wherein the chamber compresses the urethra of the human when inflated; an anchor member adapted to snugly fit in the vaginal cavity, the anchor member being connected to the inflatable chamber on the posterior side of the chamber when the pessary is in its normal operating position; and an inflation tube having a first end fluidly connected to the inflatable chamber and a second end connected to an inflation valve located external to the vagina when the pessary device is in its normal operating position that permits inflation and deflation of the inflatable chamber without disturbing the fit of the anchor member.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: February 18, 1997
    Inventor: Donald F. Tutrone, Jr.
  • Patent number: 5597719
    Abstract: Intermolecular interactions between Raf-1 and human 14-3-3 proteins which regulate Raf activity are identified. Compositions and method for identifying novel drugs which modulate Raf activity in vivo are provided.
    Type: Grant
    Filed: July 14, 1994
    Date of Patent: January 28, 1997
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Ellen Freed, Rosamaria Ruggieri
  • Patent number: 5595889
    Abstract: The present invention relates to a process for integration of a chosen gene or of a specific DNA molecule into the chromosome or episome of a bacterium by cloning the gene or DNA molecule into a defective transposon which is then integrated into the chromosomal or episomal DNA of the bacteria. The defective transposon is incapable of transposition autonomously but can be induced to transpose when properly complemented. The complementation to induce transposition can be limited so that the defective transposon produces a specific number of copies and thereafter is stable. The number of copies of the defective transposon produced during the period of transposition can be estimated by the level of expression of a marker gene contained within the defective transposon.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: January 21, 1997
    Assignee: Eurolysine
    Inventors: Fran.cedilla.ois Richaud, Bruno Jarry, Koichi Takinami, Osamu Kurahashi, Anne Beyou
  • Patent number: 5583011
    Abstract: Compositions and methods are provided for the detection and treatment of Schistosoma parasites. These compositions and methods are based on nucleic acid and amino acid sequences of Schistosoma phosphofructokinase.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: December 10, 1996
    Assignee: Board of Trustees of the Leland Stanford University
    Inventor: Tag E. Mansour
  • Patent number: 5571677
    Abstract: The invention provides methods and compositons for convergent synthesis of branched polymers useful as molecular probes. The invention also includes several novel branched polymeric structures particularly useful for detecting target polynucleotides. Branched polymers of the invention comprise at least two branches: at least one branch is a target binding moiety capable of specifically binding to a target molecule of interest and one or more branches are signal generation moities capable of directly or indirectly generating a detectable signal. In accordance with the method of the invention branched polymers are assembled from components having phosphorothioate groups and/or haloacyl- or haloalkylamino groups. The phosphorothioate and haloacyl- or haloalkylamino groups react rapidly and efficiently when brought into contact to form thiophosphorylacyl- or thiophosphorylalkylamino bridges which.complete the assembly of a branched polymer.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: November 5, 1996
    Assignee: LYNX Therapeutics, Inc.
    Inventor: Sergei M. Gryaznov
  • Patent number: 5571903
    Abstract: The invention provides compositions and a method for delivering an antisense compound or probe to a target polynucleotide. The compositions of the invention comprise a plurality of compounds each having an oligonucleotide moiety from about 4 to 12 monomers in length whose 3' and/or 5' termini have been modified by the addition of one or more terminal binding moieties. Whenever the oligonucleotide moieties specifically anneal to a target polynucleotide in a contiguous end-to-end fashion, the terminal binding moieties are capable of spontaneously interacting with one another to form a covalent linkages or stable complexes so that an effective antisense compound or probe is formed. The invention facilitates the delivery of antisense compounds to their targets and reduces the likelihood of nonspecific binding to non-target structures.
    Type: Grant
    Filed: July 9, 1993
    Date of Patent: November 5, 1996
    Assignee: Lynx Therapeutics, Inc.
    Inventor: Sergei M. Gryaznov
  • Patent number: 5567592
    Abstract: A screening method for the identification of bioenhancers that increase the bioavailability of an orally administered pharmaceutical compound through the inhibition of P-glycoprotein transport activity in the gut of a mammal is disclosed. These compounds increase the systemic availability of a pharmaceutical compound when administered prior to, or concurrently with, that compound.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: October 22, 1996
    Assignee: Regents of the University of California
    Inventors: Leslie Benet, Chi Y. Wu
  • Patent number: 5559114
    Abstract: A method for treating autoimmune disease in a mammalian subject, particularly a human, which method comprises administering a therapeutically effective amount of certain 2-amino purine compounds to the subject. The compounds particularly useful are antiviral compounds exemplified by acyclovir, penciclovir and famciclovir. The compounds are administered at doses significantly higher than the dose level used to treat viral infections, e.g., doses that will result in blood plasma levels of about 3-10 micrograms/mi.
    Type: Grant
    Filed: December 16, 1994
    Date of Patent: September 24, 1996
    Inventor: Ray W. Exley
  • Patent number: 5556872
    Abstract: The present invention provides histamine derivatives and methods for using histamine derivatives as immunomodulators and in immunotherapeutics. More specifically the present invention provides methods for inhibiting at least a portion of an an antigen specific antibody response and/or a portion of a T-cell proliferative response by the immune system of a mammal comprising administering to said mammal an effective amount of a composition comprising at least one histamine derivative having binding specificity for at least one histamine receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 17, 1996
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenneth L. Melmon, Parisa Khosropour, Murray Goodman
  • Patent number: 5547868
    Abstract: Fusion enzymes having multiple segments of different biological activity including one segment having P450scc activity and at least one segment having electron-transfer activity for transferring electrons to P450scc are described along with genetic constructs for production of such enzymes and methods for their use. Methods of their use include cholesterol degradation in vitro or in vivo as well as conversion of cholesterol to other useful steroidal products including pregnenolone.
    Type: Grant
    Filed: June 9, 1993
    Date of Patent: August 20, 1996
    Assignee: Regents of the University of California
    Inventors: Walter L. Miller, Jennifer A. Harikrishna, Stephen M. Black
  • Patent number: 5529994
    Abstract: A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: June 25, 1996
    Assignee: Palo Alto Medical Foundation
    Inventors: Jack S. Remington, Fausto G. Araujo
  • Patent number: 5530890
    Abstract: A microprocessor (50) includes a main central processing unit (CPU) (70) and a separate direct memory access (DMA) CPU (72) in a single integrated circuit making up the microprocessor (50). The main CPU (70) has a first 16 deep push down stack (74), which has a top item register (76) and a next item register (78), respectively connected to provide inputs to an arithmetic logic unit (ALU) (80) by lines (82) and (84). An output of the ALU (80) is connected to the top item register (76) by line (86). The output of the top item register at (82) is also connected by line (88) to an internal data bus (90). A loop counter (92) is connected to a decrementer (94) by lines (96) and (98). The loop counter (92) is bidirectionally connected to the internal data bus (90) by line (100). Stack pointer (102), return stack pointer ( 104), mode register (106) and instruction register (108) are also connected to the internal data bus (90) by lines (110), (112), (114) and (116), respectively.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 25, 1996
    Assignee: Nanotronics Corporation
    Inventors: Charles H. Moore, Russell H. Fish, III
  • Patent number: 5527790
    Abstract: There are provided vanadium compositions for use in the treatment of hypertension, obesity and diabetes, in particular improved oral compositions comprising oxovanadium (IV) chelates of monoprotic, bidentate oxygen, oxygen and oxygen, nitrogen coordinating ligands especially kojic acid and maltol.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: June 18, 1996
    Assignee: The University of British Columbia
    Inventors: John H. McNeill, Chris Orvig
  • Patent number: 5527610
    Abstract: The invention provides a bioelastomer comprising tetrapeptide and/or pentapeptide monomeric units of the formula:R.sub.1 PGR.sub.2 G.sub.nwherein R.sub.2 is a peptide-producing residue of alanine or glycine; P is a peptide-producing residue of proline; G is a peptide-producing residue of glycine; R.sub.2 is a peptide-producing residue of glycine or alanine; and n is 0 or 1. In a further aspect of the invention, a method is provided for preventing adhesion of biological materials, such as protein, cells, and tissues, by forming a protective layer between a first surface and a second surface using the bioelastomer.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: June 18, 1996
    Assignees: The UAB Research Foundation, Bioelastics Research, Ltd.
    Inventor: Dan W. Urry
  • Patent number: 5520672
    Abstract: Polymeric materials having an inverse temperature transition, particularly bioelastic polymers comprising monomeric units selected from the group consisting of bioelastic pentapeptides, tetrapeptides, and nonapeptides, have been found to have controllable absorbent properties that can be varied with temperature or contact with liquids. The materials are selected to be in a contracted or swollen state initially, depending on the specific use. When the material is located under different conditions (such as a different temperature resulting from being either in contact with or at distance from human skin), the material undergoes swelling or contraction to switch to the other state.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: May 28, 1996
    Inventor: Dan W. Urry
  • Patent number: 5519004
    Abstract: The invention provides a bioelastomer comprising tetrapeptide and/or pentapeptide monomeric units of the formula:R.sub.1 PGR.sub.2 G.sub.nwherein R.sub.1 is a peptide-producing residue of alanine or glycine; P is a peptide-producing residue of proline; G is a peptide-producing residue of glycine; R.sub.2 is a peptide-producing residue of glycine or alanine; and n is 0 or 1. In a further aspect of the invention, a method is provided for preventing adhesion of biological materials, such as protein, cells, and tissues, by forming a protective layer between a first surface and a second surface using the bioelastomer.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 21, 1996
    Assignees: The UAB Research Foundation, Bioelastics Research Ltd.
    Inventor: Dan W. Urry